Background. Cystatin C has recently been shown to be associated with incident type 2 diabetes. This study aims to validate this association and to study the impact of baseline adiposity. Methods. We investigated the 3-year diabetes incidence in 2849 participants from the French Data of an Epidemiological Study on the Insulin Resistance syndrome study, without overt kidney disease. Odds ratios (ORs) associated with cystatin C were adjusted for classical diabetes risk factors and interactions between cystatin C and these risk factors were studied. Results. Baseline serum cystatin C was significantly associated with incident diabetes on univariate analysis (OR/1 SD of log cystatin C: 1.74; 95% confidence interval [CI] 1.33-2.28; P = 0.0001) and after adjustment for age and gender (OR 1.55; 95% CI 1.15-2.10; P = 0.0039). This association was independent of serum creatinine-derived measures of baseline renal function and independent of fasting plasma glucose and HbA1c. When body mass index (BMI), waist circumference or baseline insulin resistance index were used as covariates, there was an interaction with cystatin C level. Cystatin C was associated only with incident diabetes for people with BMI, waist
A B S T R AC T
Background. Cystatin C has recently been shown to be associated with incident type 2 diabetes. This study aims to validate this association and to study the impact of baseline adiposity. Methods. We investigated the 3-year diabetes incidence in 2849 participants from the French Data of an Epidemiological Study on the Insulin Resistance syndrome study, without overt kidney disease. Odds ratios (ORs) associated with cystatin C were adjusted for classical diabetes risk factors and interactions between cystatin C and these risk factors were studied. Results. Baseline serum cystatin C was significantly associated with incident diabetes on univariate analysis (OR/1 SD of log cystatin C: 1.74; 95% confidence interval [CI] 1.33-2.28; P = 0.0001) and after adjustment for age and gender (OR 1.55; 95% CI 1.15-2.10; P = 0.0039). This association was independent of serum creatinine-derived measures of baseline renal function and independent of fasting plasma glucose and HbA1c. When body mass index (BMI), waist circumference or baseline insulin resistance index were used as covariates, there was an interaction with cystatin C level. Cystatin C was associated only with incident diabetes for people with BMI, waist circumference or insulin resistance index ≥ median value with OR (95% CIs), respectively: 1.35 (0.98-1.84, P = 0.0625); 1.39 (1.01-1.91, P = 0.0441) and 1.41 (1.02-1.94, P = 0.0398). Conclusions. Cystatin C was associated with 3-year incident diabetes but only in people with central adiposity or insulin resistance. This should be considered in further studies assessing the clinical relevance of its prognostic value.
I N T RO D U C T I O N
Measurement of plasma cystatin C has been proposed to be superior to creatinine-based methods for estimating glomerular filtration rate (GFR) [1, 2] , as this 13.3 kDa protein is almost completely cleared from the circulation by glomerular filtration [3] .
Recently, cystatin C has been shown to predict incident type 2 diabetes [4] . Furthermore, in a nested case-control study design in the Western New York Health Study, elevated cystatin C levels predicted progression from normal fasting plasma glucose (FPG) to prediabetes (FPG between 5.6 and 6.9 mmol/L) [5] . However, non-renal factors [age, weight, Creactive protein (CRP), male gender and cigarette smoking] were associated with cystatin C levels, after adjustment for creatinine clearance [6] . Cystatin C levels also correlated with body mass index (BMI) in the Framingham Offspring Study [7] and in the National Health and Nutrition Examination Survey III participants, those with BMI ≥30 kg/m 2 had higher levels of cystatin C levels when compared with those with BMI <25 kg/m 2 [8, 9] . Cystatin C levels also correlated with the number of the metabolic syndrome components per individual in several studies [10] [11] [12] [13] .
Adipose tissue secretes cystatin C [14] , suggesting possible interactions between adiposity and the predictive value of this biomarker for incident diabetes. We used a large French cohort with a low prevalence of obesity [Data from an Epidemiological Study on the Insulin Resistance syndrome (D.E.S.I. R.) cohort] to study the incidence of diabetes according to cystatin C and adiposity.
M AT E R I A L S A N D M E T H O D S

Study design and participant selection
We studied men and women aged 36-71 years, who participated in the Year 6 follow-up examination of the D.E.S.I.R. study [15] . Participants were volunteers who attended free periodic health examinations provided by the French social security at 10 health examination centres in western France. In total, 5212 men and women were recruited in 1994-1996 and were followed by 3-year examinations over 9 years. The protocol was approved by the ethics committee of Kremlin Bicêtre Hospital, Paris, and all participants signed an informed consent.
Serum cystatin C was assayed on 3489 of the 4111 people who attended the Year 6 examination. Of these, 3426 had information on FPG and diabetes medications available from the Year 6 examination. FPG was obtained after fasting ≥8 h. 3312 did not have diabetes in Year 6 (FPG <7.0 mmol/L and no glucose-lowering treatment); 3132 had no overt signs of renal dysfunction (estimated GFR ≥60 mL/min/1.73m 2 and negative for dipstick proteinuria, eGFR definition below); 3126 had waist and BMI measured and 2849 had data available for determining whether they had diabetes at Year 9. The 57 incident cases of diabetes were identified by FPG ≥7.0 mmol/L or treatment for diabetes at the Year 9 examination (Figure 1 ).
Study visit procedures and anthropometric measurements
Two measures of blood pressure and heart rate were taken in a supine position after 5 min rest; mean values were used. Weight and height were measured in lightly clad participants; BMI was calculated. The waist circumference, the smallest circumference between the lower ribs and the iliac crests, was measured. Fat mass was assessed by impedance using a TBF 300P balance from Tanita (Neuilly-sur-Seine, France).
The family history of diabetes and treatment for diabetes and hypertension were noted. Hypertension was defined by systolic/diastolic blood pressures ≥140/90 mmHg or being treated for hypertension. Smoking habits (never, ever and current), alcohol consumption (grams per day of alcohol from wine, beer, cider and spirits, classed as zero, <20, 20-40, ≥40 g/day, respectively) and degree of physical activity [classed as little (or sedentary), moderate and more intensive activity] were assessed using a self-administered questionnaire.
Biochemical assessment
All biochemical measurements were from one of the four French health-centre laboratories located at Blois, Chartres, La Riche or Orléans. FPG was measured by the glucose-oxidase method in fluoro-oxalated plasma using a Technicon RA100 or an Advia 1650 (Bayer Diagnostics, Puteaux, France) or a LAB20, a Delta or an AU400 Olympus (Rungis, France). HbA1c was quantified by high-performance liquid chromatography using an L9100 automated ion-exchange analyser (Hitachi/ Merck-VWR, Fontenay-sous-Bois), a Radiant 1 (Bio-Rad, Marne la Coquette, France) or by immunoassay using a DCA2000 (Bayer Diagnostics, Puteaux, France). Glucose and HbA1c were standardized between laboratories according to gender and age. Insulin was measured in the La Riche laboratory by a microparticle enzyme immunoassay with an AXSYM automated analyser (Abbott, Rungis, France).
Serum cystatin C, microalbuminuria and CRP were determined by nephelometry using a BNII nephelometer (Behring, Reuil Malmaison, France). Proteinuria was evaluated by Labstix 8SG and Multistix 8SG urine reagent strips (AMES/ Bayer diagnostics, Puteaux, France), creatinine by the Jaffe method, cholesterol, triglycerides, GGT [gamma-glutamyl transpeptidase], ALT [alanine transaminase] by enzymatic methods using AVADIA 1650 (Bayer Diagnostics, Puteaux, France), Lab Delta (Konelab, Evry, France) or AU400 (Olympus, Rungis, France).
The HOMA2-IR and HOMA2-B insulin resistance and insulin secretion indices were calculated for those with glucose levels between 3 and 23 mmol/L and insulin between 20 and 300 pmol/L, using software available from the HOMA calculator: http://www.dtu.ox.ac.uk/homacalculator/index.php [16, 17] . At follow-up, five participants were treated by secretagogues, so their insulin and HOMA data have been recoded as missing data. Approximately 10% of participants had insulin levels which were out of the range for calculation. GFR was estimated according to the simplified formula of the Modification of Diet in Renal Disease (MDRD) study: eGFR-MDRD = 186 × (serum creatinine/88.4) −1.154 × age −0.203 × (0.742 if female) [18] . Microalbuminuria was defined as albuminuria >20 mg/L. The metabolic syndrome was defined by the American Heart Association/National Heart, Lung and Blood Institute criteria [19] .
Statistical analysis
Data were analysed using Statistical Analysis System (version 9.2; SAS Institute, Cary, NC). Cystatin C levels were compared between men and women by the Wilcoxon ranksum test. Non-symmetrically distributed variables were logtransformed for analysis (insulin, HOMA2-B, HOMA2-IR, triglycerides, CRP, GGT, ALT, creatinine, cystatin C). Participant characteristics are presented according to sex-specific quartiles of cystatin C and compared by ANOVA or chisquare tests, as well as by a trend test across quartiles. Data are presented as mean ± SD for untransformed variables; by geometric mean ×/÷ exp(SD of log e transformed variable) for log-transformed variables; by n (%) for categorical variables. Correlations with the baseline cystatin C levels were defined by Spearman rank correlation analysis.
The association between baseline cystatin C and the 3-year change in metabolic parameters was studied by linear regression analysis, after adjustment for age and gender.
The baseline characteristics (at Year 6 of the study) of those who developed type 2 diabetes over the 3 years of follow-up were compared with those who did not develop diabetes, using t-tests for continuous variables and χ 2 for categorical variables. The relationship between incident diabetes and cystatin C was further studied by logistic regression and the standardized odds ratios (ORs) are presented for 1 SD of the logarithm of cystatin C. Interactions were tested between each of the adjustment variables and the logarithm of cystatin C and ORs are presented in strata when P interaction was <0.15. The relation between incident diabetes and cystatin C, according to BMI strata, is presented graphically, after adjustment for age, gender, eGFR and FPG.
R E S U LT S
Baseline characteristics
The mean age of the 2849 study participants was 53 ± 10 years; 49% were men and the median cystatin C level was 0.76 mg/L (interquartile range: 0.69-0.84). The median cystatin C level in men was 0.05 mg/L greater than that in women (0.79 versus 0.74 mg/L, respectively, P < 0.0001). The median eGFR was 80 mL/min/1.73 m 2 (interquartile range: 73-89). Table 1 F I G U R E 1 : Study participant flow diagram.
shows the characteristics of participants stratified into sexspecific quartiles of cystatin C levels. Higher cystatin C levels were associated with older age, higher BMI and waist circumference, higher prevalence of hypertension and dyslipidaemia, higher HbA1c, FPG and HOMA-IR (Table 1 ). The Spearman correlation coefficient between cystatin C and BMI was 0.28, waist 0.35, insulin 0.14 and HOMA-IR 0.15. eGFR decreased with increasing quartiles of cystatin C.
Comparing the 2849 study participants with the 1262 who were not included due to missing data at baseline (cystatin C, anthopometric measures, diabetes or signs of renal disease at Year 6) or at Year 9 (diabetes status), participants were of similar age and gender, but had a worse cardiovascular profile and higher insulin levels. However, the absolute values of any differences were small. For example, for glomerular filtration as calculated by the MDRD formula, the mean values were 80.1 versus 82.2 mL/min/1.73 m 2 in those studied. The participants included in the analysis were broadly representative of the general population without signs of renal disease.
Of the 2849 participants, 57 developed diabetes during the 3 years of follow-up. People with incident diabetes were significantly older (57 ± 8 versus 53 ± 10 years, P = 0.0094) and were more likely to be men (63 versus 49%, P = 0.0352) compared with those without diabetes at Year 9 (see Table 2 ). People who developed diabetes had higher BMI (29.1 ± 3.9 versus 25.3 ± 3.7 kg/m 2 , P < 0.0001) and waist measurements (men 98.4 ± 9.3 versus 90.0 ± 9.2 cm, women 91.6 ± 10.5 versus 79.4 ± 10.7 cm; P < 0.0001 for both), and consumed more alcohol. They had a higher FPG level (6.31 ± 0.42 versus 5.31 ± 0.50 mmol/L, P < 0.0001), higher HbA1c (5.97 ± 0.45 Mean ± SD for symmetrically distributed variables, geometric mean ×/÷ SD for variables log-transformed for analysis, or n (%).
a Variables log-transformed for analysis.
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A.T. Reutens et al. Smoking habits did not differ between these two groups. Levels of GGT, ALT and triglycerides were higher in those who developed diabetes, as well as baseline serum creatinine (83.9 ×/÷ 1.2 versus 79.0 ×/÷ 1.2 μmol/L; P = 0. 0026) and cystatin C levels (0.82 ×/÷ 1.16 versus 0.76 ×/÷ 1.16 mg/L, P < 0.0001). High density lipoprotein-cholesterol was lower in those who developed diabetes. Those who developed diabetes had a lower eGFR compared with those without incident diabetes, but this trend was not statistically significant. There was no difference in prevalence of microalbuminuria or cardiovascular disease between the two groups.
Association of baseline cystatin C with 3-year changes in metabolic factors
Cystatin C was significantly associated with the 3-year change in FPG, after adjustment for age, gender and change in BMI (Table 3) . However, there was no statistically significant association between baseline cystatin C and changes in insulin, HOMA2-IR, HOMA2-B, BMI or waist circumference.
Association of baseline cystatin C with incident diabetes
For incident diabetes in multivariable-adjusted analyses (shown in Table 4 ), cystatin C was a significant risk factor after adjusting for age and gender and remained significantly associated after adjustment for lifestyle factors (smoking, alcohol intake or physical activity) and or for family history of diabetes. The association between baseline cystatin C and 
O R I G I N A L A R T I C L E
C y s t a t i n C a n d i n c i d e n t d i a b e t e s incident diabetes was independent of renal function, CRP, hypertension, lipid levels, GGT or presence of baseline metabolic syndrome. Cystatin C remained a significant predictor of diabetes onset within 3 years, despite adjustment for baseline FPG, HbA1c or beta cell function assessed by HOMA2-B.
There was a significant interaction between adiposity and the association of cystatin C with diabetes incidence. When adjusted for anthropometric measures of obesity (BMI, waist circumference or fat mass), the P values for the interactions of cystatin C with BMI, waist circumference and fat mass for progression to diabetes were 0.0558, 0.1455 and 0.0460, respectively: the relationship of cystatin C level with new-onset diabetes differed for people who were below and above the median. The association was not significant for BMI, waist circumference or fat mass less than the median (<25.0 kg/m 2 , 85 Interactions were tested between variables used in adjustments and ORs for strata (variables are dichotomized according to the median) are shown where interactions were present (P < 0.15). cm or 27%, respectively). However, in those who were overweight or obese, there was a trend towards cystatin C being predictive of diabetes (odds ratio = 1.35, P = 0.0625). Figure 2 shows that baseline cystatin C was associated with incident diabetes in people with BMI ≥25 kg/m 2 , after adjusting for age, gender, baseline eGFR and FPG (P = 0.0252), but not in people with BMI <25 kg/m 2 . For people with waist circumference ≥85 cm, cystatin C was an independent predictor of diabetes (P = 0.0441, Table 4 ). Likewise, the relationship with fat mass showed that cystatin C was significantly associated with incident diabetes in people with high fat mass (≥27%, P = 0.0486) but not in those with fat mass less than the median level. For both insulin and HOMA2-IR, again cystatin C was only associated with incident diabetes in the more insulin resistant (Table 4) .
D I S C U S S I O N
In this cohort of D.E.S.I.R. study participants, cystatin C was associated with increased incidence of diabetes when adjusted for sex and age. Although this association was unaffected by renal function, inflammation or baseline glycaemic status, the hypothesis that cystatin C independently predicted diabetes onset was not confirmed for people with normal BMI, waist circumference or fat mass. However, cystatin C was an independent predictor of diabetes in people with high waist circumference, fat mass or insulin resistance and there was a trend for significance for BMI. Therefore, the use of cystatin C in this cohort further improved diabetes risk prediction only in the subset of people who had central adiposity and insulin resistance. However, in clinical practice, cystatin C would be unlikely to improve risk prediction, because this subset is already considered at high risk for developing diabetes.
Our finding that BMI and other adiposity measures were associated with the cystatin C level confirms the need to exclude adiposity as a confounder when interpreting studies using cystatin C to estimate renal function. This may explain results such as those of Young et al. in their analysis of the Framingham Offspring Study, which measured visceral and subcutaneous adipose tissue volume using computed tomography. They found that adipose tissue volume was not associated with chronic kidney disease when using serum creatinine-based equations, but was associated when serum cystatin-based estimations were used [20] . The link found between renal disease and adiposity in their results may in part reflect the confounding influence of visceral fat on cystatin C levels (which therefore do not purely reflect glomerular filtration).
During the follow-up period of this D.E.S.I.R. analysis, the cystatin C level was not significantly associated with changes in BMI, waist circumference, HOMA2-B or HOMA2-IR, but was associated with rise in the FPG level over 3 years. The lack of significant relationship with the change in HOMA2 indices was unexpected, since it was anticipated that the relationship between cystatin C and adiposity would cause progression to diabetes by increased insulin resistance and/or beta cell dysfunction. However, HOMA2 calculations provide only surrogate assessments of insulin sensitivity and beta cell function.
In the Beaver Dam Eye Study, adjustment for BMI markedly decreased the association of cystatin C with 15-year incidence of diabetes in the group with chronic kidney disease or proteinuria [4] . Furthermore, cystatin C showed a similar association with incident diabetes in those with and without renal dysfunction. The D.E.S.I.R. analysis confirms that adiposity significantly affects the association of cystatin C and incident diabetes and adds new information that the association is not present in the lean participants of the D.E.S.I.R. study.
Potential mechanisms may explain the relationship between obesity and serum cystatin C concentration. It has been reported that cystatin C secretion from adipose tissue explants was 2-to 3-fold higher in obese compared with nonobese people [14] . Cystatin C was highly expressed in omental and subcutaneous adipose tissue, in adipocytes, preadipocytes, endothelial cells and macrophages [14] .
Furthermore, a variant (G/G genotype) of the CST3 gene encoding cystatin C is associated in a complex manner with the evolution of BMI and waist circumference in six European cohorts [21] followed for development of corpulence from 7 years up to several decades. This implies that cystatin C may not only be a biomarker for adiposity and hence be associated with diabetes onset, but it may somehow influence development of obesity. Mechanisms are uncertain, but could involve interaction between cystatin C and various cathepsins, which have been implicated in adipogenesis [22] .
Our findings may also indicate that a decrease in renal function, shown by a slight elevation in cystatin C level, predicts future diabetes. In the Insulin Resistance Atherosclerosis Study, the highest and lowest quintiles of eGFR, with mean eGFR values of 60.8 and 109.0 mL/min/1.73 m 2 , respectively, predicted incident diabetes after 5.2 years of follow-up [23] . Although the eGFR abnormality more often seen in prediabetes is increased eGFR, indicating glomerular hyperfiltration [24] , a recent metaanalysis showed that there was a significant association between the metabolic syndrome and the development of eGFR <60 mL/min/1.73 m 2 and this association strengthened as the number of metabolic syndrome components increased [25] . In a population-based study of randomly sampled individuals without pre-existing diabetes, higher waist circumference and BMI were both independently associated with eGFR <60 mL/min/1.73 m 2 [26] . Studies employing glycaemic clamps to examine insulin sensitivity in older males showed a direct positive association between insulin sensitivity and GFR, an association that was still significant after adjustment for age, glucometabolic and cardiovascular risk factors [27] . Therefore, it is plausible that renal dysfunction and increased risk of diabetes may both reflect an underlying state of insulin resistance and hyperinsulinaemia. This may injure the kidney by promoting formation of intrarenal fibrotic and mitogenic growth factors, increasing mesangial cell proliferation, increasing endothelin 1 levels and impairing endothelial function [28] . However, as previously mentioned, in this D.E.S.I.R. analysis, a relatively limited index of insulin resistance (HOMA) was used.
Limitations of the present study were the relatively restricted age group of participants (35-71 years at baseline) and the short 3-year follow-up period for assessing development of diabetes. Oral glucose tolerance tests were not performed, so the number of people with diabetes may have been underestimated. Most participants in the D.E.S.I.R. cohort were Caucasian (93.9%) and our findings cannot be extrapolated to other ethnicities [29] . The strength of this study is the availability of data on multiple diabetes risk factors and the inclusion of a large number of individuals with normal body weight which provided the opportunity to test the interaction between adiposity and the role of cystatin C in the prediction of type 2 diabetes.
Conclusions
In summary, cystatin C levels predicted incident diabetes independently of baseline measures of renal function or of glycaemic parameters. In addition, we observed a significant interaction between adiposity and the association of cystatin C with incident diabetes. This association remained independently predictive only in people with a higher baseline BMI, waist circumference or fat mass, or higher insulin resistance. These findings suggest a complex relationship between adiposity, glycaemic homeostasis and cystatin C; further studies are needed to evaluate this.
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